Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The LOGIC 2 Trial A Phase II, Multi-center, Open-label Study of Sequential LGX818/MEK162 Combination Followed by a Rational Combination With Targeted Agents After Progression, to Overcome Resistance in Adult Patients With Locally Advanced or Metastatic BRAF V600 Melanoma

Next Previous
Search
Trial Profile

The LOGIC 2 Trial A Phase II, Multi-center, Open-label Study of Sequential LGX818/MEK162 Combination Followed by a Rational Combination With Targeted Agents After Progression, to Overcome Resistance in Adult Patients With Locally Advanced or Metastatic BRAF V600 Melanoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Binimetinib (Primary) ; Buparlisib (Primary) ; Capmatinib (Primary) ; Encorafenib (Primary) ; Infigratinib (Primary) ; Ribociclib (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms LOGIC-2
  • Sponsors Array BioPharma; Novartis; Pfizer

    • Most Recent Events

    • 05 Feb 2023 Status changed from active, no longer recruiting to completed.
    • 04 Dec 2022 Planned End Date changed from 31 Oct 2022 to 6 Jan 2023.
    • 04 Dec 2022 Planned primary completion date changed from 31 Oct 2022 to 6 Jan 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top